Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:29:05 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:AGNPF from 2023-04-20 to 2024-04-19 - 20 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-11 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
2024-04-01 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
2024-03-27 12:05U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
2024-01-31 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
2024-01-11 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
2023-12-27 16:01U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Closing of Private Placement
2023-12-27 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Increase to Private Placement
2023-12-12 19:43U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Private Placement
2023-11-30 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
2023-11-22 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
2023-11-08 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
2023-09-06 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
2023-08-08 07:00U:AGNPFNews ReleaseAlgernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
2023-07-14 18:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
2023-06-27 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
2023-06-06 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
2023-06-05 07:00U:AGNPFNews ReleaseAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
2023-05-31 07:19U:AGNPFNews ReleaseAlgernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
2023-05-05 17:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Announces Closing of Rights Offering
2023-04-20 07:00U:AGNPFNews ReleaseAlgernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time